Not a traditional drug phase: spleen diameter for Liver Cirrhosis
This retrospective cross-sectional diagnostic study compared the diagnostic performance of ultrasound-measured spleen thickness (ST) and spleen diameter (SD) against esophagogastroduodenoscopy (EGD) for gastroesophageal varices (GOV) and high-risk varices (HRV) detection in patients with compensated cirrhosis. The authors, including senior physicians in infectious diseases and ultrasound, reviewed the medical records and the following data were recorded on a case report form: participants' demographic, etiologic, and laboratory data; SD, ST, portal vein diameter (PVD) and spleen vein diameter (SVD) values; liver stiffness measurement (LSM), spleen stiffness measurement (SSM) by transient elastography (TE); and EGD results.
Official registry: https://clinicaltrials.gov/study/NCT07920744 · Fifth Affiliated Hospital, Sun Yat-Sen University · enrollment listed as 364
What this phase means
This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.
They plan to enroll about 364 people at Zhuhai. Taking part typically means study visits and measurements plus check-ins.
Official title (unrewritten)
The Value of Spleen Thickness and Spleen Diameter for Gastroesophageal Varices Diagnosis in Compensated Cirrhosis
Interventions: spleen diameter, spleen thickness, esophagogastroduodenoscopy (EGD)
Primary outcome (registry wording): Gastroesophageal Varices
Who it is for (from inclusion criteria)
- Ages 18 Years to any
- compensated cirrhosis;
Who the registry excludes
- history of hepatic decompensation, such as ascites, EVB, and hepatic encephalopathy;
- non-cirrhotic portal hypertension;
- digestive system malignancies such as hepatocellular carcinoma, pancreatic carcinoma, or other malignant tumors infiltrating the digestive system;
- acute liver disease, or serum total bilirubin ≥ 100 μmol/L;
- history of splenectomy;
- acute or chronic portal vein thrombosis;
- concomitant HIV infection;
Public study contact (from the registry)
Xi Liu
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Sites listed on ClinicalTrials.gov
1 listed- the Fifth Affiliated Hospital, Sun Yat-sen University — Zhuhai, Guangdong, China (recruiting)
FAQ about this NCT record
Is NCT07920744 still recruiting?
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07920744?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07920744?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary